MARKET

GMDA

GMDA

Gamida Cell Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.87
+0.27
+4.02%
Opening 14:43 12/04 EST
OPEN
6.73
PREV CLOSE
6.60
HIGH
7.00
LOW
6.63
VOLUME
118.48K
TURNOVER
--
52 WEEK HIGH
7.70
52 WEEK LOW
2.600
MARKET CAP
339.62M
P/E (TTM)
-5.8665
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Gamida Cell to Host Virtual Pipeline Deep Dive
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a virtual event discussing the company’s pipeline, including omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant, and GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy, on Wednesday, December 9, 2020 at 8:00 a.m. ET.
Business Wire · 2d ago
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 5d ago
Gamida Cell to Present at Upcoming Conferences
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Executive Officer of Gamida Cell, will present at two virtual conferences in December:
Business Wire · 11/24 13:01
We're Keeping An Eye On Gamida Cell's (NASDAQ:GMDA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 11/16 15:17
Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 11:00 a.m. ET.
Business Wire · 11/04 13:01
Greenlighting Gamida Cell
Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset.The cell therapy biotech now trades at half its 2018 post IPO price despite a likely approval and launch of omidubicel in 2021.The stock seems undervalued on a "sum of the parts" evaluation basis.  A full investment analysis follows in the paragraphs below.
Seekingalpha · 10/27 20:09
Gamida Cell, Be The Match BioTherapies Report Expansion Of Strategic Collaboration For Advanced Cell Therapy In Phase 3 Development
Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene
Benzinga · 10/13 12:04
Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration
Gamida Cell and Be The Match BioTherapies® today announced an expansion of their strategic collaboration for investigational omidubicel.
Business Wire · 10/13 12:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GMDA. Analyze the recent business situations of Gamida Cell Ltd. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GMDA stock price target is 15.83 with a high estimate of 20.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 15.79M
% Owned: 31.91%
Shares Outstanding: 49.47M
TypeInstitutionsShares
Increased
5
126.26K
New
14
309.17K
Decreased
9
1.23M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.43%
Pharmaceuticals & Medical Research
+1.41%
Key Executives
Non-Executive Chairman/Independent Director
Robert Blum
Chief Executive Officer/Director
Julian Adams
Chief Financial Officer
Shai Lankry
Chief Operating Officer
Tzvi Palash
Chief Scientific Officer
Tracey Lodie
Other
Joshua Hamermesh
Other
Thomas Klima
Other
Ronit Simantov
Other
Jas Uppal
Independent Director
David Fox
Independent Director
Shawn Tomasello
Independent Director
stephen Wills
Non-Executive Independent Director
Nurit Benjamini
Non-Executive Independent Director
Ofer Gonen
Non-Executive Independent Director
Kenneth Moch
Non-Executive Independent Director
Michael Perry
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GMDA
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Gamida Cell Ltd stock information, including NASDAQ:GMDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GMDA stock methods without spending real money on the virtual paper trading platform.